REMEGEN(SH:688331) Zheng Quan Zhi Xing·2025-03-27 12:27Core Viewpoint - The internal control evaluation report of Rongchang Biopharmaceuticals indicates that the company has maintained effective internal controls over financial reporting and has not identified any significant deficiencies in both financial and non-financial reporting [1][2]. Internal Control Objectives - The objectives of the internal control system are to ensure legal compliance in management, asset security, and the accuracy of financial reporting, thereby enhancing operational efficiency and supporting strategic development [2]. Internal Control Evaluation Conclusion - The company has concluded that there are no significant deficiencies in financial reporting internal controls as of the evaluation date [2][3]. - There are also no significant deficiencies identified in non-financial reporting internal controls [2][3]. - No factors affecting the evaluation conclusion have occurred between the evaluation date and the report issuance date [2]. Internal Control Evaluation Scope - The evaluation covered all major units, businesses, and high-risk areas, with 100% of the total assets and revenues included in the evaluation scope [3]. Internal Control Evaluation Standards - The company has established quantitative and qualitative standards for identifying internal control deficiencies, maintaining consistency with previous years [4][6]. - Quantitative standards for financial reporting deficiencies include thresholds based on asset and revenue misstatements [4][6]. Internal Control Deficiencies and Remediation - During the reporting period, the company identified some general deficiencies in financial reporting internal controls, which have been rectified without impacting the overall control objectives [7]. - Similarly, general deficiencies in non-financial reporting internal controls were also identified and addressed [7]. Future Plans - The company plans to further enhance its internal control system and strengthen internal supervision to mitigate various risks and promote healthy development in 2025 [7].